GAITHERSBURG, Md.--(BUSINESS WIRE)--VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious diseases such as AIDS and cardiovascular disease, will present eight abstracts at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Washington, DC, from May 17-22, 2010. The abstracts represent results of the company’s clinical trials for Lexgenleucel-T (VRX496™), an autologous cell and gene therapy product for the treatment of HIV/AIDS; preclinical trials of the company’s prophylactic HIV vaccine, VRX1273; and work utilizing the company’s spliceosome mediated RNA trans-splicing (SMaRT™) platform technology.
